Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

Q: What type of study is this?

This is a Phase 2 study (also classified as: Observational).

Marı́a Buti; Heiner Wedemeyer; Soo Aleman; Vladimir Chulanov; В. А. Морозов; Olga Sagalova; T.V. Stepanova; Robert G. Gish; Andrew Lloyd; Katja Deterding; Dmitry Manuilov; Audrey Lau; A. Osinusi; Marvin Rock; C Kim; Srinath Pandey; Brajesh K. Singh; Pietro Lampertico

doi:10.1055/s-0045-1810985

Key Points

Patients reported improved health status after treatment with bulevirtide for chronic hepatitis delta.
In a phase 3 trial, those receiving bulevirtide showed significant benefits compared to untreated patients.
The MYR301 trial evaluated patient-reported outcomes and highlighted the treatment's positive impact.
Findings suggest bulevirtide may be a valuable option for managing chronic hepatitis delta, needing further validation.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 3 MYR301 trial shows improved health status in chronic hepatitis delta patients treated with bulevirtide, implying its effectiveness.

Abstract

Introduction: Patients with chronic hepatitis delta (CHD) who received 48 weeks (W) of bulevirtide (BLV) 2 mg monotherapy previously reported greater improvements in their perceived health status compared with patients who received no treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Buti et al. (2025) studied this question.

synapsesocial.com/papers/68c194029b7b07f3a0618701 https://doi.org/10.1055/s-0045-1810985

View at Publisher

Ask AI

Bookmark

Share

Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading